Leqembi, the first drug shown to slow Alzheimer’s, has been approved by the FDA, but most U.S. patients will not be able to receive treatment for months.
. The doctor will then decide what caused the condition, such as Alzheimer’s, Parkinson’s disease, a stroke or brain injury.
Care providers will need a plan in place for how patients will be monitored after they begin taking the drug. Before health systems begin offering drugs like Leqembi, they must first develop plans for delivering the drugs, which can take months. The drug has not yet received full approval from the FDA, something that could happen later this year.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: